RAD51 and cancer: It disrupted RAD51 binding to DNA, inhibits nucleoprotein filament formation and greatly increases the sensitivity of cancer cells to a wide range of genotoxic drugs, including the DNA cross-linking agents cisplatin and mitomycin C, as well as Topoisomerase 1 (Topotecan) and Topoisomerase 2 (doxorubicin) inhibitors.